title: [Diabetic nephropathy: emerging treatments].
abstract: Diabetic nephropathy is a leading cause of end-stage renal disease worldwide. The mainstay of treatment has been management of hyperglycaemia, blood pressure and proteinuria using hypoglycemic agents, ACE inhibitors, and angiotensin receptor blockers. Since 2000, new therapeutic strategies began to emerge targeting the biochemical activity of glucose molecules on the renal tissue. Various substances have been studied with varying degrees of success, ranging from vitamin B to camel's milk. Silymarin reduces urinary excretion of albumin, tumor necrosis factor (TNF)-α, and malondialdehyde in patients with diabetic nephropathy and may be considered as a novel addition to the anti-diabetic nephropathy armamentarium. Although some results are promising, studies on a larger scale are needed to validate the utility of these molecules in the treatment of the DN.
authors.affiliation: Service de néphrologie, groupe hospitalier de la Pitié-Salpêtrière, 47-83, boulevard de l'Hôpital, 75013 Paris, France.
authors.forename: Victor
authors.initials: V
authors.lastname: Gueutin
authors.affiliation: Service de néphrologie, groupe hospitalier de la Pitié-Salpêtrière, 47-83, boulevard de l'Hôpital, 75013 Paris, France.
authors.forename: Marion
authors.initials: M
authors.lastname: Gauthier
authors.affiliation: Service de néphrologie, groupe hospitalier de la Pitié-Salpêtrière, 47-83, boulevard de l'Hôpital, 75013 Paris, France.
authors.forename: Maud
authors.initials: M
authors.lastname: Cazenave
authors.affiliation: Service de néphrologie, groupe hospitalier de la Pitié-Salpêtrière, 47-83, boulevard de l'Hôpital, 75013 Paris, France. Electronic address: hassan.izzedine@psl.aphp.fr.
authors.forename: Hassane
authors.initials: H
authors.lastname: Izzedine
mesh_terms: D000324:Adrenocorticotropic Hormone / Q000627:therapeutic use; D000493:Allopurinol / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000933:Antifibrinolytic Agents / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D003928:Diabetic Nephropathies / Q000188:drug therapy* / Q000503:physiopathology; D004318:Doxycycline / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D004872:Ergocalciferols / Q000627:therapeutic use; D006728:Hormones / Q000627:therapeutic use; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D008301:Maleimides / Q000627:therapeutic use; D015282:Octreotide / Q000627:therapeutic use; D010431:Pentoxifylline / Q000627:therapeutic use; D011728:Pyridones / Q000627:therapeutic use; D011733:Pyridoxamine / Q000627:therapeutic use; D012838:Silymarin / Q000627:therapeutic use; D014803:Vitamin B Complex / Q000627:therapeutic use
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000933:Antifibrinolytic Agents; D018931:Antineoplastic Agents, Hormonal; D000975:Antioxidants; D050071:Bone Density Conservation Agents; D004791:Enzyme Inhibitors; D004872:Ergocalciferols; D006728:Hormones; D007211:Indoles; D008301:Maleimides; D011728:Pyridones; D012838:Silymarin; D014803:Vitamin B Complex; D000493:Allopurinol; D011733:Pyridoxamine; C084656:paricalcitol; C099154:ruboxistaurin; D000324:Adrenocorticotropic Hormone; C093844:pirfenidone; D004318:Doxycycline; C560078:pamrevlumab; D015282:Octreotide; D010431:Pentoxifylline
keywords: Agents nouveaux; Chronic kidney disease; Diabetes mellitus; Diabetic nephropathy therapy; Diabète sucré; Maladie rénale chronique; Novel agents; Traitement de la néphropathie diabétique